Livings CJ - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Page 1

Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.

Paulissen JHJ, Seddik AH, Dunton KJ, Livings CJ, van Hulst M, Postma MJ, de Jong LA, Freriks RD. Paulissen JHJ, et al. Among authors: livings cj. Eur J Health Econ. 2024 Jun;25(4):689-699. doi: 10.1007/s10198-023-01617-3. Epub 2023 Jul 24. Eur J Health Econ. 2024. PMID: 37486557 Free PMC article.

Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK.

Telford C, Bertranou E, Large S, Phelps H, Ekman M, Livings C. Telford C, et al. Pharmacoecon Open. 2019 Dec;3(4):559-570. doi: 10.1007/s41669-019-0134-3. Pharmacoecon Open. 2019. PMID: 31025302 Free PMC article.

Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden.

Sabale U, Ekman M, Thunström D, Telford C, Livings C. Sabale U, et al. Pharmacoecon Open. 2017 Dec;1(4):279-290. doi: 10.1007/s41669-017-0031-6. Pharmacoecon Open. 2017. PMID: 29441507 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Search Page

Filters